Practice and Guidance for Conducting Bayesian Interim Analyses in Clinical Trials

被引:0
作者
Li, Hal [1 ]
Gates, Davis [2 ]
机构
[1] Accenture, Life Sci, Biostat, 585 East Swedesford Rd, Wayne, PA 19087 USA
[2] Merck Res Lab, Late Dev Stat, Kenilworth, NJ 07033 USA
来源
WORLD CONGRESS ON ENGINEERING AND COMPUTER SCIENCE, WCECS 2013, VOL II | 2013年 / Ao,卷
关键词
Bayesian; Interim Analysis; Clinical Trails; Simulation;
D O I
暂无
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The theory and methods for the Bayesian Interim Analysis for Clinical Trials are motivators for this presentation. Introductions to the Bayesian statistics, Bayesian Inference, and interim analysis for clinical trials are provided, along with detailed discussion of the theory. Practical examples of the Bayesian interim analysis for clinical trials are provided to illustrate the methods. The Bayesian predictive probability approach, Interval estimation approach and posterior distribution summary approach on the Normal and Binomial distributed data are also discussed. Bayesian inference simulations were performed. Discussions are provided to the FDA's guidance and opinion on Bayesian analysis, as well as FDA's approval history on Bayesian analyzed clinical trials.
引用
收藏
页码:844 / +
页数:2
相关论文
共 50 条
  • [31] Design of group sequential clinical trials: A Bayesian decision theoretic approach
    Vlachos, PK
    Gelfand, AE
    [J]. AMERICAN STATISTICAL ASSOCIATION - 1996 PROCEEDINGS OF THE SECTION ON BAYESIAN STATISTICAL SCIENCE, 1996, : 152 - 157
  • [32] Designing and analyzing clinical trials for personalized medicine via Bayesian models
    Zhang, Chuanwu
    Mayo, Matthew S.
    Wick, Jo A.
    Gajewski, Byron J.
    [J]. PHARMACEUTICAL STATISTICS, 2021, 20 (03) : 573 - 596
  • [33] Robust Bayesian design and analysis of clinical trials via prior partitioning
    Sargent, DJ
    Carlin, BP
    [J]. BAYESIAN ROBUSTNESS, 1996, 29 : 175 - 193
  • [34] A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes
    Moatti, M.
    Chevret, S.
    Zohar, S.
    Rosenberger, W. F.
    [J]. METHODS OF INFORMATION IN MEDICINE, 2016, 55 (01) : 4 - 13
  • [35] Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes
    Galbraith, S
    Marschner, IC
    [J]. STATISTICS IN MEDICINE, 2003, 22 (11) : 1787 - 1805
  • [36] Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis
    Hollaender, Norbert
    Conzalez-Maffe, Juan
    Jehl, Valentine
    [J]. BIOMETRICAL JOURNAL, 2020, 62 (03) : 658 - 669
  • [37] Bayesian two-stage designs for phase II clinical trials
    Tan, SB
    Machin, D
    [J]. STATISTICS IN MEDICINE, 2002, 21 (14) : 1991 - 2012
  • [38] Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility
    Walter, S. D.
    Han, H.
    Briela, M.
    Guyatt, G. H.
    [J]. STATISTICS IN MEDICINE, 2017, 36 (09) : 1506 - 1518
  • [39] Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods
    Hulot, JS
    Cucherat, M
    Charlesworth, A
    Van Veldhuisen, DJ
    Corvol, JC
    Mallet, A
    Boissel, JP
    Hampton, J
    Lechat, P
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (03) : 299 - 306
  • [40] A tutorial on sensitivity analyses in clinical trials: the what, why, when and how
    Thabane, Lehana
    Mbuagbaw, Lawrence
    Zhang, Shiyuan
    Samaan, Zainab
    Marcucci, Maura
    Ye, Chenglin
    Thabane, Marroon
    Giangregorio, Lora
    Dennis, Brittany
    Kosa, Daisy
    Debono, Victoria Borg
    Dillenburg, Rejane
    Fruci, Vincent
    Bawor, Monica
    Lee, Juneyoung
    Wells, George
    Goldsmith, Charles H.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2013, 13